Roivant Sciences (NASDAQ:ROIV) Posts Earnings Results, Beats Expectations By $0.04 EPS

Roivant Sciences (NASDAQ:ROIV) posted its earnings results on Monday. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.04, Zacks reports. Roivant Sciences had a negative return on equity of 14.65% and a net margin of 3,827.42%.

Roivant Sciences Trading Up 0.2 %

NASDAQ ROIV opened at $10.89 on Monday. Roivant Sciences has a 12-month low of $9.76 and a 12-month high of $13.06. The company has a fifty day simple moving average of $11.51 and a two-hundred day simple moving average of $11.60. The stock has a market cap of $7.93 billion, a P/E ratio of 1.93 and a beta of 1.25.

Insider Activity

In related news, COO Eric Venker sold 100,000 shares of Roivant Sciences stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $11.32, for a total transaction of $1,132,000.00. Following the completion of the sale, the chief operating officer now owns 606,525 shares of the company’s stock, valued at $6,865,863. The trade was a 14.15 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Sciences Ltd. Roivant purchased 16,845,010 shares of the business’s stock in a transaction that occurred on Monday, January 13th. The stock was acquired at an average price of $20.00 per share, for a total transaction of $336,900,200.00. Following the acquisition, the director now owns 96,650,341 shares in the company, valued at $1,933,006,820. This trade represents a 21.11 % increase in their position. The disclosure for this purchase can be found here. Insiders have sold 1,942,629 shares of company stock valued at $23,034,486 over the last ninety days. 7.90% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on ROIV shares. Cantor Fitzgerald upgraded shares of Roivant Sciences to a “strong-buy” rating in a report on Thursday, January 30th. HC Wainwright restated a “buy” rating and issued a $18.00 target price on shares of Roivant Sciences in a research note on Wednesday, November 13th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $17.93.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.